HOMA-IR: Is Insulin Resistance Building While Your Glucose Looks Normal?

What HOMA-IR actually measures about insulin resistance

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a calculated index that uses two simultaneous fasting measurements — fasting insulin and fasting glucose — to estimate the degree of insulin resistance in the body. It was developed in 1985 by Matthews and colleagues as a mathematical model of the steady-state relationship between glucose and insulin in the fasting state.

Insulin is a hormone produced by the pancreatic beta cells that signals cells throughout the body, particularly in muscle, fat tissue, and the liver, to absorb glucose from the bloodstream. In insulin resistance, cells become less responsive to this signal. The pancreas compensates by producing more insulin to achieve the same blood glucose effect, resulting in elevated fasting insulin levels. For a period, blood glucose may remain within the normal range despite underlying insulin resistance, which is why fasting glucose alone is a relatively insensitive early marker of metabolic dysfunction.

Over time, sustained insulin resistance increases the risk of progression to type 2 diabetes, is associated with cardiovascular disease, and is central to the pathophysiology of metabolic syndrome. Comprehensive reviews of insulin resistance biomarkers establish fasting insulin as one of the most clinically informative early markers for metabolic health assessment and cardiometabolic risk prediction. The earlier insulin resistance is identified, the greater the opportunity to address the metabolic trajectory through lifestyle, monitoring, and clinical management.

The compensatory hyperinsulinemia that fasting glucose alone misses

As insulin resistance develops, pancreatic beta cells secrete progressively more insulin to keep blood glucose within the normal range — a state known as compensatory hyperinsulinemia. Fasting glucose can remain below 100 mg/dL for years while fasting insulin is quietly climbing. HOMA-IR multiplies both inputs, so when insulin is elevated and glucose is still normal, the product reflects that compensatory state. Either marker alone misses it: glucose reads normal; insulin alone requires a separate reference frame; the ratio surfaces the discordance between the two.

This is the core editorial value of HOMA-IR. The TyG index (triglyceride-glucose index) offers an alternative surrogate for insulin resistance that uses fasting triglycerides and glucose instead of insulin, making it calculable when fasting insulin is not available. Emerging evidence suggests the TyG index may outperform HOMA-IR for predicting metabolic syndrome in certain populations. Fasting insulin alone is also independently informative — a fasting insulin above 10–12 µIU/mL is commonly used as a clinical marker of concern — but it requires a separate reference frame and does not capture the glucose side of the equation. HbA1c and fasting glucose are later-stage markers: glucose begins rising only after insulin resistance has been sustained long enough to impair beta-cell compensation, meaning normal HbA1c and glucose do not exclude insulin resistance.

HOMA-IR is most informative in the early-to-middle stages of insulin resistance. Once beta-cell exhaustion sets in and insulin production falls despite persistent glucose elevation — as occurs in late type 2 diabetes — HOMA-IR can underestimate resistance, because the model assumes intact beta-cell function. This is why it is a fasting-state model, not a dynamic challenge, and why it should be interpreted alongside clinical context rather than in isolation.

How HOMA-IR is calculated from glucose and insulin

The standard formula uses glucose expressed in mmol/L:

HOMA-IR = (Fasting insulin [µIU/mL] × Fasting glucose [mmol/L]) / 22.5

If glucose is measured in mg/dL, as is commonly reported in the United States, the formula is adjusted to:

HOMA-IR = (Fasting insulin [µIU/mL] × Fasting glucose [mg/dL]) / 405

For example, a person with a fasting insulin of 8 µIU/mL and a fasting glucose of 90 mg/dL would have:

HOMA-IR = (8 × 90) / 405 = 720 / 405 = 1.78

This result falls in a mildly elevated range suggestive of early insulin resistance in most reference frameworks.

The numerator captures the product of two simultaneous fasting measures: the amount of insulin the pancreas is producing and the glucose level it is managing. A high insulin level alongside a normal or high glucose level indicates that more insulin than expected is required to maintain glucose regulation — the defining feature of insulin resistance. A low insulin level alongside normal glucose is the expected pattern in individuals with good insulin sensitivity.

Both values must be drawn in a fasted state. An 8–12 hour fast is required, with 12 hours preferred; a morning draw is standard. Eating before the test will raise both insulin and glucose acutely, producing a falsely elevated HOMA-IR that does not reflect the resting steady-state the formula is designed to capture.

What your HOMA-IR score means in practice

• <1.0 — Optimal insulin sensitivity, consistent with healthy beta-cell function and cellular insulin responsiveness
• 1.0–1.9 — Normal range with mild insulin resistance possible; appropriate monitoring, and metabolic risk factors should inform clinical assessment
• 1.9–2.9 — Early insulin resistance likely; metabolic health review warranted with lifestyle factors and additional biomarkers assessed
• >2.9 — Significant insulin resistance, associated with metabolic syndrome criteria; clinical evaluation indicated

Two interpretive frames are in common use. The conventional cutoff used by most laboratory reference ranges flags values above 2.0 as elevated. A preventive or optimal frame treats values above 1.0 as a signal worth monitoring, particularly in individuals with other metabolic risk factors. Neither frame is universally standardized.

Cut-off values vary across published literature and between population groups. Ethnicity, age, body composition, and menstrual cycle phase can all influence HOMA-IR independently of insulin resistance. Because laboratories use different insulin assays — and fasting insulin assays are not standardized across platforms — absolute HOMA-IR values are not directly comparable between different laboratories. HOMA-IR is most reliable when trended within the same laboratory using the same insulin assay over time. Reference ranges vary by laboratory and individual; results should be interpreted by a qualified provider in clinical context. HOMA-IR is not a diagnosis.

What drives HOMA-IR up or down

Adiposity and insulin signaling

Visceral fat — fat stored around the abdominal organs rather than subcutaneously — is metabolically active and secretes inflammatory cytokines and free fatty acids that interfere with insulin signaling in the liver and muscle. Individuals with central adiposity, including elevated waist circumference even without a high BMI, commonly have elevated HOMA-IR relative to their body weight. This is why HOMA-IR can be elevated in individuals who appear lean if visceral fat distribution is unfavorable.

Physical inactivity compounds this effect. Skeletal muscle is the primary site of insulin-mediated glucose disposal, accounting for roughly 80% of postprandial glucose uptake in insulin-sensitive individuals. Physical inactivity reduces muscle glucose transporter expression (particularly GLUT4) and reduces the rate of non-oxidative glucose disposal, which contributes to insulin resistance. Research consistently shows that regular resistance and aerobic exercise are associated with lower HOMA-IR, through improvements in muscle glucose transporter expression and visceral fat reduction.

Diet, energy surplus, and hepatic glucose output

Chronic excess energy intake, particularly from refined carbohydrates and added sugars, drives repeated postprandial insulin surges, promotes visceral fat accumulation, and over time reduces insulin receptor sensitivity. Dietary patterns associated with lower HOMA-IR in population studies include higher fiber intake, greater adherence to Mediterranean-style eating, and lower intake of refined carbohydrates and ultra-processed foods.

The liver is both a target and a driver of insulin resistance. When hepatic insulin signaling is impaired, the liver continues releasing glucose despite elevated insulin levels — a pattern of impaired suppression of hepatic glucose output. Elevated liver enzymes, particularly ALT, alongside a high HOMA-IR score can point toward hepatic insulin resistance and warrant evaluation for fatty liver disease (NAFLD/MASLD).

Circadian biology and stress hormones

Short sleep duration and poor sleep quality are associated with acute and chronic increases in insulin resistance. A single night of partial sleep deprivation can produce measurable increases in fasting insulin and HOMA-IR in controlled experimental settings. Shift work and circadian misalignment produce longer-term metabolic consequences through disruption of cortisol rhythms and downstream glucose metabolism.

Cortisol is a counter-regulatory hormone that raises blood glucose by stimulating gluconeogenesis in the liver and opposing insulin action in peripheral tissues. Chronically elevated cortisol — from sustained psychological stress, poor sleep, or conditions such as Cushing's syndrome — contributes to insulin resistance and elevated HOMA-IR. Fasting cortisol may be worth assessing in individuals with unexplained insulin resistance, particularly when accompanied by other features of cortisol excess.

Hormonal context: PCOS and compensatory hyperinsulinemia

Insulin resistance is present in an estimated 65–80% of women with polycystic ovary syndrome (PCOS), frequently independent of body mass index. Insulin directly stimulates ovarian theca cells, contributing to the excess androgen production characteristic of the condition. In this population, HOMA-IR can be elevated while fasting glucose remains in the normal range, making it a more sensitive early indicator of metabolic involvement than glucose measured alone — a direct expression of the compensatory hyperinsulinemia that HOMA-IR is designed to surface.

The metabolic panel that surrounds HOMA-IR

• Fasting insulin — The numerator of the HOMA-IR formula; its absolute value is independently informative. A fasting insulin above 10–12 µIU/mL is often flagged as concerning. Pairing the raw insulin value with HOMA-IR shows whether resistance is primarily insulin-driven or glucose-driven.
• Fasting glucose — The denominator of the HOMA-IR formula; reflects hepatic glucose output. Glucose rises only after insulin resistance has persisted long enough to impair beta-cell compensation, so a normal fasting glucose does not exclude an elevated HOMA-IR.
• HbA1c — A 3-month average of blood glucose. When HbA1c is normal but HOMA-IR is elevated, this confirms the pre-diabetic metabolic stage where the pancreas is still compensating and glucose has not yet risen into the dysglycemic range.
• Triglycerides — Elevated in insulin resistance through increased hepatic VLDL production. Triglycerides are also the basis of the TyG index, the leading alternative surrogate for insulin resistance when fasting insulin is unavailable.
• hs-CRP — A marker of systemic inflammation that co-travels with insulin resistance in metabolic syndrome. hs-CRP adds a cardiovascular-risk layer to the HOMA-IR metabolic picture.
• TyG index — The primary alternative surrogate for insulin resistance; uses triglycerides and glucose instead of insulin, making it calculable when fasting insulin is not available.

The right retest window for HOMA-IR

HOMA-IR is a responsive marker. Improvements in diet, exercise, and sleep can produce measurable changes in fasting insulin and HOMA-IR within 8–12 weeks of sustained lifestyle change. For individuals actively monitoring a metabolic intervention, retesting every 3 months provides a meaningful signal without over-testing.

Because fasting insulin assays are not standardized across laboratories, absolute HOMA-IR values are not directly comparable between different labs. Trend HOMA-IR within the same laboratory using the same insulin assay. Switching labs mid-monitoring introduces assay variability that can obscure real change or create apparent change where none exists.

Draw conditions matter. Use a morning draw after a 12-hour fast (8 hours is the minimum; 12 hours is preferred). Avoid vigorous exercise the evening before the draw — acute exercise can transiently alter glucose metabolism and affect the fasting insulin reading. If a result is unexpectedly high on first testing, recheck with a confirmatory morning fasted draw before clinical escalation. Dehydration, acute illness, or a failed fast are common sources of artifactual elevation.

When a high HOMA-IR warrants further metabolic workup

A HOMA-IR above 2.9 is associated with metabolic syndrome criteria in most reference frameworks and warrants a structured metabolic workup. This typically includes review of fasting insulin, fasting glucose, HbA1c, triglycerides, HDL-C, blood pressure, and waist circumference. If early type 2 diabetes is suspected — particularly where fasting glucose is approaching or above 100 mg/dL — an oral glucose tolerance test (OGTT) provides a dynamic assessment that HOMA-IR, as a fasting-state model, cannot replicate.

HOMA-IR has important limitations that affect when it is and is not appropriate. It is invalid in type 1 diabetes and after pancreatic insufficiency, because the model assumes intact beta-cell function — in these settings, low insulin production reflects the underlying condition rather than insulin sensitivity. It is also unreliable in individuals on exogenous insulin, where the administered insulin dose confounds the fasting insulin measurement. In late type 2 diabetes, where beta-cell exhaustion has reduced insulin output despite persistent glucose elevation, HOMA-IR may underestimate the true degree of insulin resistance.

Used within its appropriate scope — as a fasting-state surrogate in individuals with intact beta-cell function, trended within the same laboratory — HOMA-IR is one of the most practical and informative tools available for early metabolic monitoring. Superpower is built on the principle that this kind of proactive, data-driven insight should be accessible to everyone. Learn more about the Superpower manifesto.